Nav: Home

AHA, Verily Life Sciences, AstraZeneca announce winner of $75M One Brave Idea research award

October 05, 2016

DALLAS, TX and SOUTH SAN FRANCISCO, CA, October 5, 2016 - The American Heart Association (AHA), Verily Life Sciences LLC (formerly Google Life Sciences), an Alphabet company, and AstraZeneca, today announced that the One Brave Idea™ research award will be granted to Dr. Calum MacRae, chief of Cardiovascular Medicine at Boston's Brigham and Women's Hospital, to support his visionary approach to understanding and addressing coronary heart disease (CHD) and its devastating consequences.

"After launching a global search effort earlier this year, we are proud to announce the selection of Dr. Calum MacRae as the leader of our One Brave Idea initiative," said Nancy Brown, chief executive officer of the American Heart Association. "Dr. MacRae and his newly-formed, world-renowned, multidisciplinary team were selected from among hundreds of applicants throughout the world to receive this landmark award that will provide support over a five-year period for a research project focused on uncovering the causes of heart disease, including previously unrecognized signals marking the transition from wellness to the earliest, yet still largely invisible stages of disease."

"The vision for One Brave Idea was to create an innovative model for scientific research by bringing together significant resources and diverse organizations to support a single vision," said Dr. Jessica Mega, chief medical officer of Verily. "With our partners at the American Heart Association and AstraZeneca, we hope this initiative will inspire other new approaches to funding and catalyze meaningful advances for patients living with coronary heart disease and other conditions."

The AHA, Verily and AstraZeneca launched One Brave Idea in January 2016 as the largest one-time award to a single team to find a cure to end CHD and its consequences. In addition to receiving funding, Dr. MacRae and his team will have access to the combined expertise and resources of the three partner organizations, which include the AHA's medical and scientific prowess, Verily's technical expertise in device engineering, data analytics and software development for clinical applications, and AstraZeneca's scientific insights and mentoring.

"AstraZeneca, AHA and Verily share a common purpose and passion for patients and science. We believe that this collaboration will ignite and inspire ideas, opening the door to find a big, brave solution," said Dr. Greg Keenan, vice president and head of US Medical Affairs of AstraZeneca. "Dr. MacRae's research not only has the potential to advance our understanding of coronary heart disease and its underlying consequences, but also allows us to combine resources to take a truly innovative and multidisciplinary approach in addressing cardiovascular disease."

"I'm grateful to the AHA, Verily and AstraZeneca for believing in my research vision and showing their support by selecting our remarkable team as the recipients of the One Brave Idea award," said Dr. MacRae. "The earliest indicators of coronary heart disease remain unknown, both on a genetic and molecular level. If we unearth and characterize novel markers in people genetically prone to heart disease or with early stages of the disease, we can potentially screen the broader population at a younger age to identify those same markers and discover preventative or pre-disease interventions that can break the cascade towards disease."
LIVE Virtual Press Conference

Dr. MacRae and representatives from the AHA, Verily and AstraZeneca will be hosting a virtual press conference via YouTube Live, today, October 5, 2016 at 2:30 pm ET/11:30 am PT to provide additional details around One Brave Idea and the winning research project.

To participate in the press conference, click

The presentation will be archived on YouTube following the event.

About the American Heart Association

The American Heart Association is devoted to saving people from heart disease and stroke - America's No. 1 and No. 5 killers. We team with millions of volunteers to fund innovative research, fight for stronger public health policies, and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation's oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit or call any of our offices around the country. Follow us on Facebook and Twitter.

About Verily Life Sciences

Verily is a life sciences research and engineering organization focused on improving healthcare outcomes by applying the latest scientific and technological advances to significant problems in health and biology. By combining unparalleled capabilities in data organization and analytics services with robust scientific and product engineering expertise, Verily is targeting the dual objectives of creating tools and user-friendly platforms that capture a deeper and broader set of health data, and organizing the data so that it is useful and actionable. Verily partners with leading life sciences, medical device, and government organizations to leverage deep domain expertise and resources that enable exponentially faster development, meaningful advancements, and deployment at scale.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in Inflammation, Infection and Neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:

Media Contacts:

American Heart Association - Alex Barbieri, (214) 783-7751,

Verily - Dan Budwick, Pure Communications, Inc., (973) 271-6085,

AstraZeneca - Michele Meixell, (302) 885-2677

American Heart Association

Related Heart Disease Articles:

Arsenic in drinking water may change heart structure raising risk of heart disease
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, according to a new study by researchers at Columbia University Mailman School of Public Health.
New health calculator can help predict heart disease risk, estimate heart age
A new online health calculator can help people determine their risk of heart disease, as well as their heart age, accounting for sociodemographic factors such as ethnicity, sense of belonging and education, as well as health status and lifestyle behaviors.
Wide variation in rate of death between VA hospitals for patients with heart disease, heart failure
Death rates for veterans with ischemic heart disease and chronic heart failure varied widely across the Veterans Affairs (VA) health care system from 2010 to 2014, which could suggest differences in the quality of cardiovascular health care provided by VA medical centers.
Heart failure: The Alzheimer's disease of the heart?
Similar to how protein clumps build up in the brain in people with some neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, protein clumps appear to accumulate in the diseased hearts of mice and people with heart failure, according to a team led by Johns Hopkins University researchers.
Women once considered low risk for heart disease show evidence of previous heart attack scars
Women who complain about chest pain often are reassured by their doctors that there is no reason to worry because their angiograms show that the women don't have blockages in the major heart arteries, a primary cause of heart attacks in men.
More Heart Disease News and Heart Disease Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...